Anaphylaxis is a medical emergency that requires immediate attention. Learn what to do if you develop anaphylaxis and how you can help prevent this potentially life-threatening allergic reaction.
Benralizumab has been successful in reducing the frequency of asthma attacks in this population of severe asthma sufferers. Specifically, those who used the drug experienced fewer asthma attacks in the course of a year than did those who did not use the drug. Patients also tended to tolerate the drug well, with few or no adverse side effects. More details on safety outcomes will be released in coming months. However, there do not appear to be any red flags in terms of the drugs safety at this time.
To date, the clinical trials on benralizumab have included around 2500 people, ages 12 and up, who suffer from severe asthma and who have what is known as eosinophilic inflammation. The drug, which is an injection therapy, is intended for people who have not been able to control their asthma with conventional asthma medications, including inhalers and pills. Benralizumab is not the first injectable drug that has been developed for severe asthma. Other companies, including GlaxoSmithKline and Teva Pharmaceutical Industries produce drugs that are similar to benralizumab in a number of ways.
The impact of benralizumab has not been compared to that of the other injectable drugs yet. So far, AstraZeneca’s drug has only been tested against placebos and other types of asthma drugs that are not injected. However, whereas the injectable drugs created by GlaxoSmithKline and Teva Pharmaceutical Industries act on a protein that activates eosinophils, the cells that are believed to cause asthma, benralizumab acts directly on these cells. Given that benralizumab works via a more direct mechanism than other injectable drugs, it may turn out to be more effective. Another potential benefit of benralizumab is convenience and ease of use. Unlike other injectables, benralizumab comes in a prefilled syringe and thus does not require the additional preparation that many injectable drugs do.
About 1 in 10 asthma sufferers has severe asthma, totaling approximately 30 million people worldwide. The drug could therefore have a significant global impact on asthma. Additionally, AstraZeneca plans to test the drug in other phase III trials for use in patients with severe chronic obstructive pulmonary disease, potentially expanding the impact of the drug. AstraZeneca plans to submit the drug for regulatory approval in both the United States and European Union by the end of 2016.